Home » Pipeline

Pipeline

January 3, 2020

Company	Drug/Device	Medical Condition	Status
Topas Therapeutics	TPM203	pemphigus vulgaris	Phase 1 trial initiated in 24 subjects with pemphigus vulgaris at seven sites in Germany
Cullinan Oncology	CLN-081 and VK-2019	non-small cell lung cancer	Phase 1/2a trial initiated dosing subjects
Arcus Biosciences Genentech Roche	AB928, atezolizumab and regorafenib	colorectal cancer	Phase 1/1b trial initiated
Arcus Biosciences Genentech Roche	AB928, atezolizumab and gemcitabine/nab-paclitaxel	pancreatic cancer	Phase 1/b trial initiated
Longeveron	Longeveron Allogeneic Mesenchymal Stem Cells	Alzheimer’s disease	Phase 1 trial initiated dosing 33 subjects with mild Alzheimer’s disease
NeuroVive	KL1333	primary mitochondrial disease	Phase 1a/b trial initiated in healthy subjects
Qu Biologics	QBECO SSI	Crohn’s disease	Phase 2 trial initiated enrolling 170 subjects with moderate to severe Crohn’s disease at sites in Canada, the U.S. and Europe
Selecta Biosciences	SEL-212	gout	Phase 2 trial initiated enrolled 150 subjects at 49 sites
Arrowhead Pharmaceuticals	ARO-AAT	liver disease	Phase 2 trial initiated enrolling subjects with AATD associated liver disease
Aravive Biologics	AVB-500	kidney fibrosis	Phase 2a trial initiated enrolling subjects with biopsy-proven IgAN and excreting one to three grams of protein daily in their urine
iView Therapeutics	IVIEW-1201	acute adenoviral conjunctivitis	Phase 2 trial initiated dosing subjects 15 years or older with acute adenoviral conjunctivitis in India and China
Sensorion	SENS-401	sudden sensorineural hearing loss	Phase 2 trial initiated enrolling subjects with severe or profound sudden sensorineural hearing loss at multiple centers
Urovant Sciences	URO-902	overactive bladder	Phase 2a trial initiated enrolling 80 female subjects with overactive bladder who have failed oral pharmacologic therapy
Aldeyra Therapeutics	ADX-2191	proliferative vitreoretinopathy	Phase 3 trial initiated enrolling subjects at multiple centers
ContraFect Corporation	Exebacase	staph aureua bacteremia	Phase 3 trial initiated enrolling 350 subjects with staph aureus bacteremia, including right-sided endocarditis at sites in the U.S.
Akari Therapeutics	Nomacopan	hematopoietic stem cell transplant-related thrombotic microangiopathy	Phase 3 trial initiated enrolling pediatric subjects with hematopoietic stem cell transplant-related thrombotic microangiopathy
Phathom Pharmaceuticals	Vonoprazan	helicobacter pylori infection	Phase 3 trial initiated enrolling 975 subjects with h.pylori infection
InxMed Co.	IN10018	cancer	IND Approval granted by the China National Medical Products Administration
Daiichi Sankyo AstraZeneca	ENHERTU	HER2 positive unresectable or metastatic breast cancer	Approval granted by the FDA
Astellas Pharma Seattle Genetics	Padcev	bladder cancer	Accelerated approval granted by the FDA
Forward Science	Orapeutic	opioid free oral pain management	FDA approval granted
VERO Biotech	GENOSYL	nitric oxide gas for inhalation	FDA approval granted
Ortho Dermatologics	ARAZLOTM	acne vulgaris	FDA approval granted
Eisai	DAYVIGO	insomnia	FDA approval granted
Allergan	Ubrevly	migraines	FDA approval granted
Intra-Cellular Therapies	Caplyta	schizophrenia	FDA approval granted
Merck	Ervebo	Ebola virus	Approval granted by the FDA